Among them, alpelisib is now clinically available to treat hormone receptor-positive/HER2-negative, PIK3CA-mutated breast cancer, whereas inavolisib, more potent than alpelisib in vitro, is under investigation in phase III clinical trials [12, 13]. Here, NR4A1 is linked to breast carcinoma.